Compare Page
AOD-9604 vs Tesamorelin
Quick verdict: AOD-9604 and Tesamorelin both target fat reduction in research contexts, but they come from completely different pharmacological lineages. AOD-9604 is a modified fragment of human growth hormone (hGH 177–191) that mimics GH’s lipolytic activity without its growth-promoting or diabetogenic effects. Tesamorelin is a full-length GHRH analog that stimulates endogenous GH release, driving fat loss through sustained GH-mediated pathways — and is the only peptide FDA-approved specifically for visceral fat reduction.
Read the full peptide profiles: AOD-9604 | Tesamorelin.
At a Glance: AOD-9604 vs Tesamorelin
Mechanism of Action
AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the C-terminal fragment of human growth hormone (amino acids 177–191), modified with a tyrosine residue at position 1. It was designed to isolate GH’s fat-metabolising activity from its growth-promoting, diabetogenic, and IGF-1-stimulating effects. Preclinical research demonstrated that AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat synthesis) in adipose tissue without binding the GH receptor or elevating IGF-1 levels. The exact molecular target remains debated — some evidence suggests it interacts with a distinct, uncharacterised receptor on adipocytes, while other data points to beta-3 adrenergic receptor involvement.
Tesamorelin takes the opposite pharmacological approach. Rather than isolating a fragment of GH’s activity, it works upstream to stimulate the body’s own GH production. Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH 1–44) with a trans-3-hexenoic acid modification that improves stability. It binds GHRH receptors on pituitary somatotrophs, triggering pulsatile GH release that closely mimics physiological secretion patterns. The resulting GH elevation drives lipolysis, promotes lean mass preservation, and improves metabolic parameters through the full GH/IGF-1 axis — including effects on visceral adipose tissue, insulin sensitivity, and hepatic fat.
The fundamental mechanistic distinction is: AOD-9604 attempts to deliver GH’s lipolytic effect as an isolated fragment; Tesamorelin delivers the full GH response through physiological stimulation. This means Tesamorelin produces broader effects (muscle, bone, metabolism) alongside fat reduction, while AOD-9604 theoretically offers more targeted fat loss without GH-related side effects. However, as clinical trial data would demonstrate, theoretical selectivity and clinical efficacy are not the same thing. For Tesamorelin’s comparison with other GH-axis peptides, see Tesamorelin vs CJC-1295 and Tesamorelin vs Sermorelin.
Research Evidence
Tesamorelin has the dramatically stronger evidence base. It completed Phase III clinical trials and received FDA approval in 2010 (marketed as Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The pivotal trials demonstrated significant reductions in visceral adipose tissue (VAT) — approximately 15–18% reduction versus placebo, measured by CT scan — along with improvements in trunk fat, triglycerides, and patient-reported body image. Subsequent studies have also shown Tesamorelin’s benefits on hepatic fat (NAFLD) and cognitive function in older adults, broadening its research profile beyond lipodystrophy.
AOD-9604’s clinical trajectory is markedly less successful. While preclinical studies in obese Zucker rats and mice showed promising lipolytic effects without effects on blood glucose or IGF-1, the peptide failed in Phase III human clinical trials for obesity. Metabolic Pharmaceuticals conducted a 24-week randomised controlled trial that failed to show significant weight loss versus placebo, leading to the discontinuation of clinical development. The peptide was subsequently granted GRAS (Generally Recognised as Safe) status by the FDA for use in food products in 2007, but this is a safety designation, not an efficacy approval. AOD-9604’s evidence for fat loss in humans remains weak.
This evidence disparity is the defining feature of this comparison. Tesamorelin has proven, FDA-approved efficacy for visceral fat reduction with robust clinical trial data. AOD-9604 had a compelling preclinical rationale but failed to deliver clinically meaningful fat loss in human trials. Researchers should weigh this gap carefully when selecting between these compounds for fat-metabolism studies.
Key Differences
- Clinical evidence: Tesamorelin has FDA approval and Phase III success; AOD-9604 failed Phase III for obesity and has no approved indication
- Mechanism: AOD-9604 acts directly on adipocytes as a GH fragment; Tesamorelin stimulates endogenous GH release via GHRH receptors — fundamentally different approaches
- IGF-1 effects: Tesamorelin elevates IGF-1 (through GH stimulation); AOD-9604 does not affect IGF-1 levels — this means Tesamorelin has broader anabolic effects
- Metabolic breadth: Tesamorelin improves triglycerides, hepatic fat, body composition, and potentially cognition; AOD-9604’s documented effects are limited to preclinical lipolysis data
- Safety profile: AOD-9604 has GRAS status and appears very well-tolerated; Tesamorelin can cause injection-site reactions, fluid retention, and transient glucose elevations from GH stimulation
- Visceral vs general fat: Tesamorelin specifically targets visceral adipose tissue (CT-measured); AOD-9604’s human fat-reduction data did not demonstrate regional specificity
Frequently Asked Questions
Is AOD-9604 effective for fat loss?
AOD-9604 showed promising lipolytic effects in animal models (obese mice and rats), but its Phase III clinical trial in humans failed to demonstrate significant weight loss compared to placebo. This is a critical distinction — preclinical promise did not translate to human efficacy. Tesamorelin, by contrast, has proven visceral fat reduction in randomised controlled trials and holds FDA approval for this indication.
Why did AOD-9604 fail in clinical trials?
The exact reasons remain debated. Possible factors include insufficient oral bioavailability (early trials used oral formulations), inadequate dosing, differences between rodent and human adipocyte biology, and the possibility that the GH fragment’s isolated lipolytic mechanism is insufficient to produce clinically meaningful fat loss in humans without the broader GH-axis effects. The failure highlights the challenge of translating fragment-based peptide approaches from preclinical to clinical success.
Does Tesamorelin cause the same side effects as growth hormone?
Tesamorelin stimulates endogenous GH release, so it can produce GH-related effects including fluid retention, arthralgia, and transient blood glucose elevation. However, because it stimulates pulsatile GH release (rather than providing continuous exogenous GH), the side-effect profile is generally milder than direct GH administration. The body’s negative feedback mechanisms remain intact, limiting GH elevation to physiological or near-physiological ranges.
Is AOD-9604 the same as the hGH fragment 176-191?
They are very closely related. AOD-9604 is a synthetic version of hGH amino acids 177–191 with a tyrosine modification at the N-terminus. The terms are sometimes used interchangeably in non-scientific contexts, though AOD-9604 technically refers to the specific modified compound developed by Metabolic Pharmaceuticals for clinical trials. Both share the same proposed mechanism of isolated lipolytic activity without GH receptor binding.
Can Tesamorelin help with non-HIV-related abdominal fat?
Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy. However, research has investigated its effects on visceral fat in non-HIV contexts, including age-related abdominal obesity. Studies in older adults have shown reductions in visceral fat and improvements in cardiovascular risk markers. Off-label research interest in Tesamorelin for general visceral adiposity is growing, though regulatory approval remains limited to the HIV lipodystrophy indication.
Which peptide has fewer side effects?
AOD-9604 appears to have a very favourable tolerability profile — it received GRAS status from the FDA and showed minimal adverse effects in clinical trials. However, it also showed minimal efficacy. Tesamorelin has more documented side effects (injection-site reactions, fluid retention, glucose perturbation) but also has proven clinical benefits. The tolerability advantage of AOD-9604 must be weighed against its lack of demonstrated efficacy in humans.
Are both peptides banned in sport?
Yes — both are prohibited by WADA. AOD-9604 falls under S2 as a growth hormone fragment, and Tesamorelin is classified under S2 as a growth hormone releasing factor. Both are prohibited at all times in WADA-regulated competition.
References
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID: 18057338
- Stanley TL, Chen CY, Branch KL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID: 31594769
- Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PMID: 11713212
- Stier CT, Koenig S, Lee DY, et al. Effects of the anti-obesity peptide AOD9604 on insulin resistance and lipid parameters in obese Zucker rats. Diabetes. 2004;53(Suppl 2):A385.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis. J Clin Endocrinol Metab. 2010;95(9):4291-4304. PMID: 20554713
- Thompson JL, Butterfield GE, Gylfadottir UK, et al. Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. J Clin Endocrinol Metab. 1998;83(5):1477-1484. PMID: 9589640